The Q1 2026 prints from the largest publicly traded analytical-instrument vendors are now substantially complete, with Agilent the last to report when it releases fiscal-second-quarter numbers after the close on May 27. Read against each other, the six prints from Thermo Fisher, Agilent, Bruker, Mettler-Toledo, Waters, and Revvity tell a more coherent story than any single quarter alone.
Headline revenue at the group level held up - low- to mid-single-digit organic growth was the median outcome - but underneath the headlines, end-market mix has shifted noticeably. Capex is being funded by bioprocessing, GLP-1 manufacturing, semiconductor metrology, and adjacent build-outs such as data-center cooling. It is not being funded, in any meaningful way, by US academic and government accounts, by core industrial reinvestment, or by China outside of a few project-specific pockets. This is a usable signal for procurement teams and capital planners sizing analytical-instrument spend for the rest of 2026.
Bioprocessing and GLP-1 manufacturing are the strongest pull
Bioprocessing is the cleanest end-market story across the six prints. Thermo Fisher’s pharma and biotech end market grew mid-single digits in Q1 2026, with bioproduction and clinical research called out as the engines. Agilent reported its biotech sub-market at double-digit growth, lifting the pharma end market overall to 7%. Mettler-Toledo described bioprocessing as the single fastest-growing piece of its laboratory portfolio, citing strength in intelligent sensors for bioreactor monitoring and the recent launch of a glucose sensor extending its sensor management line for biopharma manufacturing.
Waters’s first combined quarter with the former BD Biosciences and Diagnostic Solutions businesses added a fresh data point on the same theme. Inside its legacy Analytical Sciences division, the company called out high-single-digit instrument growth and mid-teens chemistry growth, with GLP-1 manufacturing volume named explicitly as one of the drivers. The newly acquired Biosciences segment contributed $232 million in the partial quarter, sitting alongside Diagnostics rather than overlapping with inline process spectroscopy workflows.
The cross-vendor pattern is that biopharma manufacturing - not academic biotech research - is what is moving instrument orders. GLP-1 manufacturing build-outs are repeatedly named on calls. Investments in single-use bioreactor instrumentation, inline glucose and metabolite sensing, and chemistry consumables for pharmaceutical QC and release testing all sit on the same demand curve.
Semiconductor metrology and data-center cooling are the surprise pull
Two of the six prints surfaced semiconductor metrology as a top-three growth driver. Bruker said its AI-driven semiconductor metrology business has exceeded $300 million in annual revenue, with bookings growth above 20% in Q1 alongside its SciY laboratory software line. Mettler-Toledo, asked directly about process analytics on the May 8 earnings call, framed the line as “doing extremely well,” tied to “all these build-outs in semiconductor, including, by the way, data centers, where these things are also used for cooling systems.” The mechanism is ultra-pure water monitoring, dissolved oxygen, and silica measurement for fab and hyperscaler facility loops.
The semi pull does not show up in every vendor’s segment file - Thermo Fisher’s industrial-and-applied bucket was flat in Q1, with mass spec and chromatography the named contributors rather than fab-side metrology - but the two vendors closest to semi metrology and inline sensor lines both flagged the same trend. Agilent’s chemicals and advanced materials end market, which carries some of the same exposure, grew 9% overall and more than 20% in its materials sub-segment, with battery-related and electronics-related testing among the named drivers.
Academic, government, and core industrial: caution persists
The flip side of the bioprocessing and semi-metrology pull is that US academic and government accounts continued to weaken. Thermo Fisher’s academic-and-government end market posted a low-single-digit decline. Bruker called the US academic line out as one of the dominant drags on its 4.4% organic revenue contraction, while flagging double-digit bookings growth from academic accounts outside the United States and pointing to NIH funding as the key swing factor for the back half of the year. Mettler-Toledo’s core industrial line was flat ex-acquisitions.
China continues to drag across the board. Bruker’s Asia Pacific region was down 10% reported. Revvity’s letter of intent to divest its China Immunodiagnostics business for up to $200 million, signed April 16 and expected to close in 2027, is the largest portfolio-pruning action of the cycle and a concrete data point on how vendors are responding to policy-induced pricing pressure and localised-manufacturing requirements.
What the cross-read suggests for buyers
For procurement teams and capex planners sizing analytical-instrument spend through the rest of 2026, the segment commentary points to three operational implications. First, bioprocessing and pharmaceutical QC supply chains are likely to stay tight; lead times for inline biopharma sensors, single-use bioreactor instrumentation, and pharma-grade chromatography consumables should be planned with the assumption that vendor backlogs are rebuilding rather than easing. Bruker’s third consecutive quarter of book-to-bill above 1.0x on its Scientific Instruments segment is the clearest signal of that.
Second, semiconductor and data-center build-outs are large enough to be visible at the segment level for at least two vendors. Plants negotiating new ultra-pure water analyzer purchases should expect tightening capacity at the sensor-manufacturer level rather than the abundance of supply that prevailed in the 2024-2025 down cycle.
Third, academic, government, and core industrial demand do not look like the place where 2026 capex unlocks. Buyers in those segments who can defer non-critical analyzer refresh decisions until the second-half reporting cycle - particularly until the NIH funding picture clarifies - have a defensible case for doing so. Segment-level reporting does not disaggregate inline process instruments from the rest of each vendor’s portfolio, so investors and procurement teams will continue to triangulate from earnings call commentary rather than from headline segment numbers alone.
Agilent’s May 27 fiscal-second-quarter release will refresh the most recent end-market read; everything above is anchored to the Q1 prints already on the tape.